Skip to main content

Capricor Therapeutics, Inc.

CAPR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001133869

No open-market purchases or sales by Capricor Therapeutics, Inc. insiders were filed in the last 90 days; 169 institutions reported holding it in 13F filings for Q2 2026, worth $941.6M in total; no superinvestor holds it.

Holders of 5% or more of CAPR

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Capricor Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of CAPR
HolderLatest formStakeChangeFirst filedLatest filingFiling
BlackRock, Inc.13G/A6.50%2.97M shares–Feb 5, 20251 filingFeb 5, 2025SEC
Vanguard Group Inc13G5.04%2.31M shares+0.09 ppfrom 4.95%Jan 30, 20253 filingsJul 29, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

4 Schedule 13D and 13G filings on Capricor Therapeutics, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on CAPR
Filed (ET)FilerFormStakeChangeEvent dateFiling
Jul 29, 202511:23 AM ETVanguard Group Inc13G5.04%2.31M shares+0.09 ppfrom 4.95%Jun 30, 2025SEC
Apr 30, 202510:58 AM ETVanguard Group Inc13G/A4.95%2.26M shares−0.05 ppfrom 5.00%Below 5%Mar 31, 2025SEC
Feb 5, 20255:28 PM ETBlackRock, Inc.13G/A6.50%2.97M shares–Dec 31, 2024SEC
Jan 30, 20259:34 PM ETVanguard Group Inc13G5.00%2.28M sharesNewDec 31, 2024SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Capricor Therapeutics, Inc. shares.

No Form 144 notices for Capricor Therapeutics, Inc. are on file.